Oxidative Stress as a biomarker for Embryo Selection in IVF Process

Projektinformationen

FERTISSIMO

ID Finanzhilfevereinbarung: 718746

DOI 10.3030/718746

Projekt abgeschlossen

EK-Unterschriftsdatum 18 Februar 2016

Startdatum 1 März 2016

Enddatum 31 August 2016

Finanziert unter

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Gesamtkosten € 71 429,00

EU-Beitrag € 50 000,00

Koordiniert durch

CARMEL DIAGNOSTICS LTD
Israel

Ziel

Abstract:
Carmel Diagnostics, established in 2009, is an SME that has developed clinical applications of its novel, proprietary, patented Thermochemiluminescence technology platform – TCL Analyzer™. Carmel has successfully completed “proof of concept” for its main applications: Embryo Selection in IVF process and Risk Stratification for CHF patients. The results were published in leading magazines. The technology enables assessment of Oxidative Stress in body fluids using it as a biomarker for clinical problems linked to levels of oxidative stress. TCL Analyzer is a stable, robust Point of Care system, now in its third generation. There is a huge need, clinical and economical, for novel biomarkers that will enable the physicians with effective embryo selection. With the goal of identifying embryos of high implantation probability, Carmel’s non-invasive solution will meet this need by providing a quantitative assessment of an embryo’s reproductive potential based on a biomarker - the oxidative profile of the culture media in which the embryo is incubated. This will allow the practitioner to improve pregnancy rates while reducing the incidence of multiple births. The Phase-1 project will be focused on preparing sound business plan, based on solid business model and commercialization strategy and to plan the activities for deploying the solution. This will include market and competition analysis, IP analysis, supply chain examination, risk assessment, and preparing roadmap for the clinical validation, product completion and the best route to bring the system to the market and launch it successfully. In June, 2014 Carmel won a prestigious grant of GFI - Grant for Fertility Innovation (by Merck Serono) that enabled it to build a series of improved, stable TCL Analyzer units to be used in the clinical studies. Eureka approved the project as well. Carmel’s experienced management is thrilled to build FERTISSIMO, the ultimate Embryo selection system based on TCL Analyzer.

Wissenschaftliches Gebiet

• medical and health sciences › clinical medicine › gynaecology › reproductive medicine
• social sciences › sociology › demography › fertility
• medical and health sciences › clinical medicine › obstetrics
• medical and health sciences › health sciences › nutrition
• medical and health sciences › clinical medicine › embryology

Programm/Programme

• H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme
• H2020-EU.3.1.3. - Treating and managing disease

Thema/Themen

• PHC-12-2015-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices

Aufforderung zur Vorschlagseinreichung

H2020-SMEInst-2014-2015

Andere Projekte für diesen Aufruf anzeigen

Unterauftrag

H2020-SMEINST-1-2015

Finanzierungsplan

SME-1 - SME instrument phase 1

Koordinator

CARMEL DIAGNOSTICS LTD

• Netto-EU-Beitrag: € 50 000,00
• Adresse: 9 BARLEV HAIM STREET ; 3608267 QIRYAT TIVON ; Israel
• KMU Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen). Ja:
  Aktivitätstyp
  Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Aktivitätstyp: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Gesamtkosten: € 71 429,00